Dechra Grows Vet Pharmaceutical Business With UK Acquisition

Dechra Pharmaceuticals PLC has officially acquired Genitrix Ltd. for roughly $8.4 million.

Dechra Pharmaceuticals PLC reported today that it has acquired Genitrix Ltd., a U.K.-based veterinary pharmaceuticals company, for about $8.4 million. An additional $1.2 million will be payable upon achievement of specific milestones, according to Dechra Pharmaceuticals, also based in the United Kingdom.

Dechra's acquisition is consistent with the company’s strategy to grow its international veterinary pharmaceutical business, said Dechra Pharmaceuticals, which has a U.S. division, Dechra Veterinary Products, in Overland Park, Kan.

“Genitrix range of equine and companion animal products enhances and complements our U.K. product portfolio,” said Ian Page, chief executive of Dechra Pharmaceuticals. “Furthermore, the recently approved canine epilepsy product, Libromide, provides future growth opportunities through potential mutual recognition in Europe. The acquisition is expected to be earnings enhancing in the first full year following ownership.”

Genitrix had revenue of about $3.7 million in the year ended March 31, 2010, according to Dechra Pharmaceuticals.


Leave a Comment


Your email address will not be published. Required fields are marked *



Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.